• Bullseye Trades
  • Posts
  • BSEM: A Multi-Catalyst MedTech Story Gaining Attention Fast

BSEM: A Multi-Catalyst MedTech Story Gaining Attention Fast

Could Be Flying Under Wall Street’s Radar👀

June 24, 2026

 This has been disseminated on behalf of BioStem Technologies

BSEM: A MedTech Transformation Story That May Be Flying Under Wall Street’s Radar!

BioStem Technologies (OTCQB: BSEM) is quietly building momentum as it expands across the regenerative medicine and advanced wound care landscape. 

While much of the market remains focused on larger healthcare names, BSEM is executing a multi-pronged strategy that includes a transformative acquisition, growing hospital penetration, strengthening board leadership, and ongoing Nasdaq uplisting ambitions. 

Powered by its proprietary BioREtain® technology platform, BSEM is steadily increasing its commercial reach across high-value healthcare settings. Zacks Small-Cap Research has placed a $25.50 price target on BSEM, highlighting what it sees as significant long-term upside as the company scales its regenerative medicine platform!

At the center of the story is a company transitioning from early-stage profitability into a broader hospital-focused MedTech platform. 

After seven consecutive profitable quarters prior to its current expansion phase, BSEM is now investing heavily into scale through the BioTissue acquisition, which significantly expanded its hospital footprint, sales infrastructure, and exposure to acute care markets. 

With more than 87% of recent revenue tied to hospital settings and multiple clinical programs underway, BSEM is positioning itself in markets with substantial long-term demand.

DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC (“SV”). Full disclaimer: https://bullseyealerts.com/disclaimer/.

NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security.

*PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received six thousand dollars cash (via Sideways Frequency) for this one day program on 6/24/26 for marketing efforts to increase public awareness of BioStem Technologies, Inc. (BSEM). SV may have also previously been compensated for similar marketing efforts. As SV has received compensation from these companies, these parties have financial interests in the securities referenced. Further, SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice.

RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions.